Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and al...

Penn researchers unveil an enhanced CAR T-cell therapy that shows high remission rates in resistant lymphoma cases, with faster production and broader immune activation.

CREATE Medicines collaborates with WestGene to advance CAR therapy initiatives and lipid nanoparticle technologies, aiming for innovative cancer treatments and effective delivery systems.

CREATE Medicines has partnered with Monash University to enhance its targeted in vivo CAR therapy platform, utilizing innovative LNP technology.

Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models TAICHUNG, Feb. 13, 2026 /PRNewswire/ — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells […]

CREATE Medicines will present groundbreaking updates in CAR therapy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting significant clinical advancements.

Orna Therapeutics shared compelling in vivo CAR program data targeting autoimmune diseases at the ASH Annual Meeting. Learn more about their innovative therapies.

Orna Therapeutics announces significant presentations on its in vivo CAR therapies targeting autoimmune diseases at the upcoming ASH Annual Meeting in Orlando.

CREATE Medicines is set to unveil pivotal clinical data on MT-302 during the SITC 40th Annual Meeting, highlighting groundbreaking CAR therapy for solid tumors.

Orna Therapeutics will highlight its innovative in vivo CAR therapy approach for autoimmune diseases at the upcoming ACR Annual Meeting in Chicago.

Ginkgo Bioworks, in partnership with STRM.BIO and UBC, is advancing in vivo CAR therapies for autoimmune diseases under ARPA-H's EMBODY initiative.

Orna Therapeutics has revealed groundbreaking preclinical data at the ASGCT Annual Meeting, showcasing its innovative in vivo CAR therapy aimed at autoimmune diseases, highlighting potent findings that could transform treatment.

Orna Therapeutics is set to present its cutting-edge in vivo CAR therapy for autoimmune conditions at the prestigious ASGCT Annual Meeting, exhibiting its groundbreaking approach in gene therapy.

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today annou...

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shif...